EGR2 in T cell tolerance
EGR2 in T cell tolerance
批准号:
9066116
负责人:
THOMAS F GAJEWSKI
金额:
$32.79万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2012
资助国家:
美国
项目状态:
已结题
起止时间:
2012-08-01 至 2017-05-31
关键词:
AutoimmunityBindingBiologyCCL1 geneCD28 geneCD3 AntigensCD8B1 geneCell physiologyCell surfaceCellsCellular biologyChIP-seqDNA cassetteDataDiacylglycerol KinaseFamilyFlow CytometryFunctional disorderGene ExpressionGene Expression ProfilingGene TargetingGenerationsGenesGoalsHumanImmuneImmune ToleranceImmunityImmunohistochemistryIn VitroInterleukin-2Knock-outLipidsMediatingModelingMutant Strains MiceNeoplasm MetastasisPathway interactionsPatientsPeripheralPhosphotransferasesPlayProcessProductionResistanceRoleSHPS-1 proteinSemaphorinsSeriesSurfaceT cell anergyT cell responseT-Cell ActivationT-LymphocyteTamoxifenTimeTumor EscapeTumor ImmunityTumor-Infiltrating LymphocytesUp-RegulationWorkanergycancer immunotherapychemokineclass-I restricted T cell-associated moleculeclinical applicationclinically relevantcytokinegene productimprovedin vivoin vivo Modelmelanomanovel strategiesnovel therapeutic interventionperipheral tolerancepreventprogramspromoterreceptorresearch studyrestorationtranscription factortumortumor microenvironment
中文摘要
描述(由申请人提供):外周免疫耐受的一个关键机制是通过T细胞无反应性过程发生的,特别是在肿瘤背景下。我们以前已经表明,上调表达的二酰基甘油激酶(DGK)家族的脂质激酶参与抑制RasGRP介导的Ras激活,并有助于T细胞功能障碍的无反应性状态。其他研究已经暗示了额外的负调节信号蛋白的上调,其可以协作以维持T细胞功能障碍。最近,通过条件敲除研究,基因表达谱和ChIP-Seq实验,我们已经确定了转录因子EGR 2作为这些负调控因子在T细胞无能中表达的中心调节因子。重要的是,已经出现了新的EGR 2驱动的靶点,它们是细胞表面标志物,可以允许流式细胞术鉴定无反应性细胞。该提议的主要目标是确定EGFR 2对肿瘤外周耐受的贡献。在具体目标1中,我们将确定在体内外周T细胞中EGFR 2的条件性缺失的影响。将评估T细胞无反应性的诱导、抗肿瘤免疫的产生和发展自身免疫的潜力。在特定目标2中,将研究T细胞生物学中EGFR 2调节基因子集的相关性。我们将重点关注分泌因子CCL 1; CRTAM/LAG 3/4-1BB的表面表达;以及Semaphorin 7A的功能作用。这些标志物的组合是否可以识别肿瘤微环境中的无反应性细胞将被确定。在特定目标3中,将评价浸润人黑素瘤的T细胞中EGFR 2及其靶标的表达,以走向临床相关性。总之,这些研究将大大拓宽和加深我们对体内EGR 2和T细胞无反应性的理解,并有望揭示可用于癌症免疫治疗的临床应用策略。
英文摘要
DESCRIPTION (provided by applicant): One critical mechanism of peripheral immunologic tolerance occurs through the process of T cell anergy, particularly in the tumor context. We previously have shown that upregulated expression of lipid kinases of the diacylglycerol kinase (DGK) family participate in the suppression of RasGRP-mediated Ras activation and contribute to T cell dysfunction in the anergic state. Other studies have implicated upregulation of additional negative regulatory signaling proteins, which may cooperate to maintain T cell dysfunction. Recently, through conditional knockout studies, gene expression profiling and ChIP-Seq experiments, we have identified the transcription factor EGR2 as a central regulator of expression of these negative regulatory factors in T cell anergy. Importantly, new EGR2-driven targets have emerged that are cell surface markers, which may allow flow cytometric identification of anergic cells. The major goal of this proposal is to determine the contribution o EGR2 towards peripheral tolerance to tumors. In Specific Aim 1 we will determine the effects of conditional deletion of EGR2 in peripheral T cells in vivo. Induction of T cell anergy, generation of anti-tumor immunity, and potential for evolving autoimmunity will be assessed. In Specific Aim 2, the relevance of a subset of EGR2- regulated genes in T cell biology will be investigated. We will focus on the secreted factor CCL1; the surface expression of CRTAM/LAG3/4-1BB; and the functional role of Semaphorin 7A. Whether combinations of these markers can identify anergic cells in the tumor microenvironment will be determined. In Specific Aim 3, expression of EGR2 and its targets in T cells infiltrating human melanoma will be evaluated, to move towards clinical relevance. Together, these studies will substantially broaden and deepen our understanding of EGR2 and T cell anergy in vivo, and are expected to uncover strategies that can have clinical application towards immunotherapy of cancer.
期刊论文(2)
专著(0)
科研奖励(0)
会议论文
DOI:
10.4049/jimmunol.1502538
发表时间:
2016-04-01
期刊:
Journal of immunology (Baltimore, Md. : 1950)
影响因子:
--
作者:
[Corrales L, Woo SR, Williams JB, McWhirter SM, Dubensky TW Jr, Gajewski TF]
通讯作者:
Gajewski TF
DOI:
10.1084/jem.20160485
发表时间:
2017-02
期刊:
The Journal of experimental medicine
影响因子:
--
作者:
[Williams JB, Horton BL, Zheng Y, Duan Y, Powell JD, Gajewski TF]
通讯作者:
Gajewski TF
Overcoming resistance to anti-PD1 immunotherapy
-
批准号:10057358
-
项目类别:
-
资助金额:$94.33万
-
财政年份:2016
-
负责人:THOMAS F GAJEWSKI
-
依托单位:
Overcoming resistance to anti-PD1 immunotherapy
-
批准号:10547757
-
项目类别:
-
资助金额:$92.71万
-
财政年份:2016
-
负责人:THOMAS F GAJEWSKI
-
依托单位:
Overcoming resistance to anti-PD1 immunotherapy
-
批准号:10737852
-
项目类别:
-
资助金额:$97.02万
-
财政年份:2016
-
负责人:THOMAS F GAJEWSKI
-
依托单位:
Overcoming resistance to anti-PD1 immunotherapy
-
批准号:9186858
-
项目类别:
-
资助金额:$94.12万
-
财政年份:2016
-
负责人:THOMAS F GAJEWSKI
-
依托单位:
Overcoming resistance to anti-PD1 immunotherapy
-
批准号:10304876
-
项目类别:
-
资助金额:$92.46万
-
财政年份:2016
-
负责人:THOMAS F GAJEWSKI
-
依托单位:
Host STING pathway in anti-tumor immunity
-
批准号:8759184
-
项目类别:
-
资助金额:$32.79万
-
财政年份:2014
-
负责人:THOMAS F GAJEWSKI
-
依托单位:
EGR2 in T cell tolerance
-
批准号:8370154
-
项目类别:
-
资助金额:$32.79万
-
财政年份:2012
-
负责人:THOMAS F GAJEWSKI
-
依托单位:
EGR2 in T cell tolerance
-
批准号:8914542
-
项目类别:
-
资助金额:$32.79万
-
财政年份:2012
-
负责人:THOMAS F GAJEWSKI
-
依托单位:
EGR2 in T cell tolerance
-
批准号:8677803
-
项目类别:
-
资助金额:$31.8万
-
财政年份:2012
-
负责人:THOMAS F GAJEWSKI
-
依托单位:
EGR2 in T cell tolerance
-
批准号:8518271
-
项目类别:
-
资助金额:$30.82万
-
财政年份:2012
-
负责人:THOMAS F GAJEWSKI
-
依托单位:
PROGRAM 3 (IMMUNOLOGY AND CANCER)
-
批准号:8518668
-
项目类别:
-
资助金额:$14.0万
-
财政年份:2012
-
负责人:THOMAS F GAJEWSKI
-
依托单位:
DGK in T Cell Regulation and Tolerance
-
批准号:7896647
-
项目类别:
-
资助金额:$39.0万
-
财政年份:2009
-
负责人:THOMAS F GAJEWSKI
-
依托单位:
DGK in T Cell Regulation and Tolerance
-
批准号:7740296
-
项目类别:
-
资助金额:$39.0万
-
财政年份:2009
-
负责人:THOMAS F GAJEWSKI
-
依托单位:
Deletion of inhibitory genes in post-thymic T cells to study immune tolerance
-
批准号:7510004
-
项目类别:
-
资助金额:$23.1万
-
财政年份:2008
-
负责人:THOMAS F GAJEWSKI
-
依托单位:
HUMAN IMMUNOLOGIC MONITORING
-
批准号:7714284
-
项目类别:
-
资助金额:$8.05万
-
财政年份:2008
-
负责人:THOMAS F GAJEWSKI
-
依托单位:
Deletion of inhibitory genes in post-thymic T cells to study immune tolerance
-
批准号:7646453
-
项目类别:
-
资助金额:$19.25万
-
财政年份:2008
-
负责人:THOMAS F GAJEWSKI
-
依托单位:
PROGRAM 3 (IMMUNOLOGY AND CANCER)
-
批准号:7714255
-
项目类别:
-
资助金额:$1.56万
-
财政年份:2008
-
负责人:THOMAS F GAJEWSKI
-
依托单位:
Countering immune resistance in the melanoma tumor microenvironment
-
批准号:8019440
-
项目类别:
-
资助金额:$27.47万
-
财政年份:2007
-
负责人:THOMAS F GAJEWSKI
-
依托单位:
Countering immune resistance in the melanoma tumor microenvironment
-
批准号:7248282
-
项目类别:
-
资助金额:$29.17万
-
财政年份:2007
-
负责人:THOMAS F GAJEWSKI
-
依托单位:
Countering immune resistance in the melanoma tumor microenvironment
-
批准号:7564792
-
项目类别:
-
资助金额:$29.17万
-
财政年份:2007
-
负责人:THOMAS F GAJEWSKI
-
依托单位:
国内基金
海外基金
登录
查看更多内容
帽结合蛋白(cap binding protein)调控乙烯信号转导的分子机制
-
批准号:32170319
-
项目类别:面上项目
-
资助金额:58.00万元
-
批准年份:2021
-
负责人:董春海
-
依托单位:
帽结合蛋白(cap binding protein)调控乙烯信号转导的分子机制
-
批准号:--
-
项目类别:--
-
资助金额:58万元
-
批准年份:2021
-
负责人:董春海
-
依托单位:
ID1 (Inhibitor of DNA binding 1) 在口蹄疫病毒感染中作用机制的研究
-
批准号:31672538
-
项目类别:面上项目
-
资助金额:62.0万元
-
批准年份:2016
-
负责人:孙跃峰
-
依托单位:
番茄EIN3-binding F-box蛋白2超表达诱导单性结实和果实成熟异常的机制研究
-
批准号:31372080
-
项目类别:面上项目
-
资助金额:80.0万元
-
批准年份:2013
-
负责人:杨迎伍
-
依托单位:
P53 binding protein 1 调控乳腺癌进展转移及化疗敏感性的机制研究
-
批准号:81172529
-
项目类别:面上项目
-
资助金额:58.0万元
-
批准年份:2011
-
负责人:杨其峰
-
依托单位:
DBP(Vitamin D Binding Protein)在多发性硬化中的作用和相关机制的蛋白质组学研究
-
批准号:81070952
-
项目类别:面上项目
-
资助金额:35.0万元
-
批准年份:2010
-
负责人:刘师莲
-
依托单位:
研究EB1(End-Binding protein 1)的癌基因特性及作用机制
-
批准号:30672361
-
项目类别:面上项目
-
资助金额:24.0万元
-
批准年份:2006
-
负责人:徐宁志
-
依托单位: